Indeed, in CGD patients, addition of IFNγ partially corrects the defect in phagocyte ROS production and restores bactericidal activity in vitro [69], and IFNγ therapy has consequently been used successfully as prophylaxis in this cohort [70]. This evidence concerns the gene IFNG and chronic granulomatous disease.